S. 133 |
One Hundred Eighteenth Congress of theUnited States of America AT THE SECOND SESSION Begun and held at the City of Washington on Wednesday, an act To extend the National Alzheimer's Project. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, This Act may be cited as the “NAPA Reauthorization Act”. Section 2 of the National Alzheimer's Project Act (42 U.S.C. 11225) is amended— (A) in paragraph (2), by striking “and coordination of” and inserting “on, and coordination of,”; (i) by redesignating subparagraphs (A) and (B) as subparagraphs (B) and (C), respectively; and (ii) by inserting before subparagraph (B), as so redesignated, the following: “(A) promotion of healthy aging and reduction and mitigation of risk factors for Alzheimer's;”; (i) by inserting “and other underserved populations, including individuals with developmental disabilities such as Down syndrome,” after “populations”; and (ii) by striking “; and” and inserting a semicolon; (D) by redesignating paragraph (6) as paragraph (7); and (E) by inserting after paragraph (5) the following: “(6) provide information on, and promote the adoption of, healthy behaviors that may reduce the risk of cognitive decline and promote and protect cognitive health; and”; (A) by inserting “, across public and private sectors,” after “Nation's progress”; and (B) by inserting “, including consideration of public-private collaborations, as appropriate” before the period; (i) in subparagraph (A), by adding at the end the following: “(xi) A designee of the Department of Justice. “(xii) A designee of the Federal Emergency Management Agency. “(xiii) A designee of the Social Security Administration. “(xiv) 2 or more other designees, as determined by the Secretary of Health and Human Services, at least one of whom has expertise in risk factors associated with the development or the progression of Alzheimer's.”; and (I) in the matter preceding clause (i), by striking “12” and inserting “15”; (aa) by striking “2 researchers” and inserting “3 researchers”; and (bb) by striking “; and” and inserting “, including at least one researcher with demonstrated experience in recruitment and retention of underrepresented groups into research or clinical trials related to dementia;”; (III) in clause (vi), by striking the period and inserting a semicolon; and (IV) by adding at the end the following: “(vii) 1 individual with a diagnosis of Alzheimer's disease; and “(viii) 1 representative from a historically underserved population whose lifetime risk for developing Alzheimer's is markedly higher than that of other populations.”; (I) by striking “an initial evaluation” and inserting “annual evaluations”; and (II) by striking “research, clinical” and inserting “research, risk reduction, public health, clinical”; (ii) in subparagraph (B), by striking “initial”; (I) in the matter preceding clause (i), by striking “initial”; and (II) in clause (ii), by inserting “and reduce disparities” before the semicolon; and (iv) in subparagraph (D), by striking “annually thereafter, an evaluation” and inserting “annual evaluations”; and (C) in paragraph (6), by striking “2025” and inserting “2035”; (i) by adding “and” after the semicolon; (ii) by striking “that includes an evaluation” and inserting “that includes— “(A) an evaluation;”; and (iii) by adding at the end the following: “(B) a summary of the Secretary's process for identifying and updating what conditions constitute Alzheimer's disease;”; and (B) in paragraph (3)(A)(ii), by inserting “and reduce disparities” before the semicolon; and (5) in subsection (h), by striking “2025” and inserting “2035”.
|